Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer

Gefitinib (Iressa, ZD-1839), a small molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) pathway, is currently under investigation in clinical trials for the treatment of colorectal cancer (CRC). However, as known, some patients develop resistance to TKIs, and the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qiong, Zhang, Daoxiang, Chen, Xiaoying, He, Lei, Li, Tianming, Xu, Xiaoping, Li, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635355/
https://www.ncbi.nlm.nih.gov/pubmed/26542452
http://dx.doi.org/10.1038/srep16082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635355/
https://www.ncbi.nlm.nih.gov/pubmed/26542452
http://dx.doi.org/10.1038/srep16082

Ejemplares similares